02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
22:37 , May 30, 2019 |  BC Extra  |  Company News

May 30 Company Quick Takes: Unity in-licenses protein for cognitive decline, plus Astellas, Organovo, Iovance

Unity in-licenses UCSF protein for cognitive improvement  Unity Biotechnology Inc. (NASDAQ:UBX) licensed from the University of California San Francisco exclusive, worldwide rights to IP relating to KLA, including its use to reverse or prevent cognitive...
21:58 , May 24, 2019 |  BioCentury  |  Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s...
23:09 , May 10, 2019 |  BioCentury  |  Product Development

Exelixis to fuel pipeline growth with Cabometyx cash flows

On the back of the successful launch of Cabometyx cabozantinib, Exelixis is not only using the increased free cash flow to expand the drug’s label, it also thinks it has the firepower to build out...
02:24 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
17:16 , Feb 22, 2019 |  BC Week In Review  |  Clinical News

Keytruda misses survival endpoints in Phase III HCC trial

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab missed the co-primary endpoints of improving overall survival (OS) and progression-free survival (PFS) in the Phase III KEYNOTE-240 trial to treat advanced hepatocellular carcinoma. Merck declined to...
02:47 , Feb 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Expansion into TNBC

With an RNA-binding small molecule that sensitizes HER2-negative cancers to Herceptin, Matt Disney’s latest study adds to the growing arsenal of preclinical therapies against triple-negative breast cancer. The only problem is the molecule may run...
22:41 , Feb 20, 2019 |  BC Extra  |  Clinical News

Keytruda misses survival endpoints in Phase III HCC trial

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab missed the co-primary endpoints of improving overall survival (OS) and progression-free survival (PFS) in the Phase III KEYNOTE-240 trial to treat advanced hepatocellular carcinoma. Merck declined to...
01:52 , Feb 8, 2019 |  BC Week In Review  |  Company News

BioMotiv, Rutgers launch TamRx

Cancer immunotherapy company TamRx LLC (Cleveland, Ohio) launched Feb. 7 from pharmaceutical accelerator BioMotiv LLC (Cleveland, Ohio), shooting to reach the clinic with its pan-TAM inhibitors in 2021. The company is based on research from...
23:45 , Feb 7, 2019 |  BC Extra  |  Company News

BioMotiv, Rutgers launch TamRx

Cancer immunotherapy company TamRx LLC (Cleveland, Ohio) launched Thursday from pharmaceutical accelerator BioMotiv LLC (Cleveland, Ohio), shooting to reach the clinic with its pan-TAM inhibitors in 2021. The company is based on research from Rutgers...